Fidelity Investments
LXEO icon

Fidelity Investments’s Lexeo Therapeutics LXEO Stock Holding History

Fidelity Investments’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$657K Buy
141,146
+116,758
+479% +$632K ﹤0.01% 3171
2026
Q1 		$140K Buy
24,388
+11,000
+82% +$78K ﹤0.01% 3657
2025
Q4 		$133K Sell
13,388
-45
-0.3% -$411 ﹤0.01% 3612
2025
Q3 		$89.2K Buy
13,433
+1,680
+14% +$8.13K ﹤0.01% 3714
2025
Q2 		$47.2K Buy
11,753
+1,889
+19% +$6.21K ﹤0.01% 3938
2025
Q1 		$34.2K Buy
9,864
+7,861
+392% +$34.8K ﹤0.01% 4024
2024
Q4 		$13.2K Buy
2,003
+1,408
+237% +$11.1K ﹤0.01% 4356
2024
Q3 		$5.38K Buy
595
+460
+341% +$5.49K ﹤0.01% 4614
2024
Q2 		$2.17K Buy
135
+122
+938% +$1.77K ﹤0.01% 4711
2024
Q1 		$204 Buy
+13
New +$203 ﹤0.01% 4916

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments's LXEO Position: Q2 2026 in Review

Fidelity Investments increased its Lexeo Therapeutics (LXEO) stake by 479% in Q2 2026, buying an estimated $632K and bringing the position to 141,146 shares worth $657K. The position accounts for ﹤0.01% of the portfolio, ranked #3171.

Fidelity Investments first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Fidelity Investments held 141,146 shares of Lexeo Therapeutics worth $657K as of Q2 2026.
  • Fidelity Investments bought 116,758 Lexeo Therapeutics shares in Q2 2026, an estimated $632K.
  • Lexeo Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3171 holding.
  • Fidelity Investments first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.